Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Aurinia Pharmaceuticals in a report issued on Thursday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will earn ($0.19) per share for the quarter. Leerink Swann also issued estimates for Aurinia Pharmaceuticals’ Q2 2018 earnings at ($0.18) EPS, Q3 2018 earnings at ($0.18) EPS and Q4 2018 earnings at ($0.19) EPS.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.10. Aurinia Pharmaceuticals had a negative return on equity of 17.54% and a negative net margin of 16,855.24%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period in the previous year, the company posted ($0.11) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis.
A number of other brokerages also recently commented on AUPH. BidaskClub raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. Seaport Global Securities reissued a “buy” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, March 16th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, January 22nd. Cantor Fitzgerald set a $16.00 price objective on Aurinia Pharmaceuticals and gave the stock an “overweight” rating in a research report on Thursday, March 15th. Finally, ValuEngine raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $10.93.
Aurinia Pharmaceuticals stock opened at $5.41 on Monday. Aurinia Pharmaceuticals has a 52-week low of $4.41 and a 52-week high of $9.83. The company has a market capitalization of $479.94, a PE ratio of -4.70 and a beta of 2.30.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its holdings in Aurinia Pharmaceuticals by 33.2% in the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after purchasing an additional 414,400 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Aurinia Pharmaceuticals by 36.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after purchasing an additional 319,639 shares in the last quarter. BlackRock Inc. acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $3,261,000. Alyeska Investment Group L.P. boosted its holdings in Aurinia Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after purchasing an additional 12,171 shares in the last quarter. Finally, Hudson Bay Capital Management LP boosted its holdings in Aurinia Pharmaceuticals by 20.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $2,039,000 after purchasing an additional 75,000 shares in the last quarter. 28.50% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Research Analysts Issue Forecasts for Aurinia Pharmaceuticals Inc’s Q1 2018 Earnings (AUPH)” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2018/03/21/research-analysts-issue-forecasts-for-aurinia-pharmaceuticals-incs-q1-2018-earnings-auph.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.